Skip to main content

Table 3 Grade 3–4 adverse events

From: Results of the observational prospective RealFLOT study

 

RealFLOT:

Preoperative

(n = 206)

RealFLOT:

Postoperative

(n = 142a)

Patients ≥ 65 in the preoperative phase

(n = 89)

Patients < 65 in the preoperative phase

(n = 117)

Patients ≥ 65 in the postoperative phase

(n = 56a)

Patients < 65 in the postoperative phase

(n = 86a)

Hematologic AEs

 Neutropenia

19.9%

16.9%

18.0%

21.4%

14.3%

18.6%

 Febrile neutropenia

4.4%

1.4%

4.5%

4.3%

1.8%

1.2%

 Anemia

0.5%

0.7%

0%

0.8%

0%

1.2%

Gastrointestinal AEs

 Diarrhea

1.5%

3.5%

2.2%

0.8%

3.6%

3.4%

 Stomatitis

0.5%

1.4%

1.1%

0%

1.8%

1.2%

 Nausea

2.4%

5.6%

3.4%

1.7%

1.8%

8.1%

 Vomiting

1.9%

3.5%

4.5%

0.8%

1.8%

4.6%

 Increases in ALT/AST

0.5%

0%

0%

0.8%

0%

0%

 Infective events (any G)

5.8%

3.5%

5.6%

6.0%

5.4%

2.3%

 Neurotoxic effects

1%

2.8%

2.2%

0%

1.8%

3.5%

 Cardiac complications

0.5%

0%

1.1%

0%

0%

0%

 Thromboembolic events (any G)

2.4%

1.4%

0%

4.3%

1.8%

1.2%

  1. a At the time of the interim analysis, 4 patients were still under postoperative treatment
  2. Abbreviations: AE adverse event; G grade